MX2020008881A - Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. - Google Patents
Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.Info
- Publication number
- MX2020008881A MX2020008881A MX2020008881A MX2020008881A MX2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A MX 2020008881 A MX2020008881 A MX 2020008881A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- methods
- treatment
- chk1 inhibitors
- chk1
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- YBYYWUUUGCNAHQ-LLVKDONJSA-N 5-[[4-[[(2r)-morpholin-2-yl]methylamino]-5-(trifluoromethyl)pyridin-2-yl]amino]pyrazine-2-carbonitrile Chemical compound C1=C(NC[C@@H]2OCCNC2)C(C(F)(F)F)=CN=C1NC1=CN=C(C#N)C=N1 YBYYWUUUGCNAHQ-LLVKDONJSA-N 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635459P | 2018-02-26 | 2018-02-26 | |
| US201862650192P | 2018-03-29 | 2018-03-29 | |
| US201862743993P | 2018-10-10 | 2018-10-10 | |
| PCT/US2019/019643 WO2019165458A1 (en) | 2018-02-26 | 2019-02-26 | Methods of treatment of cancer comprising chk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008881A true MX2020008881A (es) | 2021-01-08 |
Family
ID=67687903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008881A MX2020008881A (es) | 2018-02-26 | 2019-02-26 | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200397796A1 (enExample) |
| EP (1) | EP3758678A4 (enExample) |
| JP (2) | JP2021514979A (enExample) |
| KR (1) | KR20200126388A (enExample) |
| CN (1) | CN112469391A (enExample) |
| AU (1) | AU2019224164A1 (enExample) |
| CA (1) | CA3092079A1 (enExample) |
| MX (1) | MX2020008881A (enExample) |
| WO (1) | WO2019165458A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012176A (es) | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2020274164A1 (en) * | 2019-05-14 | 2021-11-25 | Sierra Oncology, Inc. | Methods of treating cancer using Chk1 inhibitors |
| CN120441567A (zh) | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Chk1抑制剂的合成方法 |
| BR112023002453A2 (pt) * | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481557B2 (en) * | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| US9345705B2 (en) * | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| JP6027230B2 (ja) * | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
| MX2019012176A (es) * | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. |
| AU2018278336A1 (en) * | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
-
2019
- 2019-02-26 JP JP2020544853A patent/JP2021514979A/ja not_active Withdrawn
- 2019-02-26 CN CN201980018748.5A patent/CN112469391A/zh active Pending
- 2019-02-26 US US16/975,686 patent/US20200397796A1/en not_active Abandoned
- 2019-02-26 CA CA3092079A patent/CA3092079A1/en active Pending
- 2019-02-26 KR KR1020207026214A patent/KR20200126388A/ko not_active Ceased
- 2019-02-26 WO PCT/US2019/019643 patent/WO2019165458A1/en not_active Ceased
- 2019-02-26 AU AU2019224164A patent/AU2019224164A1/en not_active Abandoned
- 2019-02-26 EP EP19757456.9A patent/EP3758678A4/en not_active Withdrawn
- 2019-02-26 MX MX2020008881A patent/MX2020008881A/es unknown
-
2023
- 2023-11-17 JP JP2023195862A patent/JP2024012649A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021514979A (ja) | 2021-06-17 |
| EP3758678A1 (en) | 2021-01-06 |
| CA3092079A1 (en) | 2019-08-29 |
| CN112469391A (zh) | 2021-03-09 |
| US20200397796A1 (en) | 2020-12-24 |
| KR20200126388A (ko) | 2020-11-06 |
| AU2019224164A1 (en) | 2020-10-01 |
| WO2019165458A1 (en) | 2019-08-29 |
| EP3758678A4 (en) | 2022-01-12 |
| JP2024012649A (ja) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202300875B (en) | Kat6 inhibitor methods and combinations for cancer treatment | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| PH12017502142A1 (en) | Tetrasubstituted aklene compounds and their use | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| EA201890968A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| MX2020006224A (es) | Metodos y terapia combinada para el tratamiento del cancer. | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| MX2020001727A (es) | Terapia de combinacion. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| IL307964A (en) | Combined treatment for cancer | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| MX2019013862A (es) | Terapia de combinacion. | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| JOP20200124A1 (ar) | طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2024009649A (es) | Tratamiento de la tos cronica, la dificultad respiratoria y la disnea. | |
| EP4706653A3 (en) | Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. |